Leigh Syndrome: Understanding Symptoms, Diagnosis, and Support for Families

What Is Leigh Syndrome?

Leigh syndrome is a severe, progressive neurodegenerative disorder caused by defects in mitochondrial energy production. It typically manifests in infancy or early childhood, with hallmark features including developmental regression, hypotonia, movement disorders, and characteristic bilateral brainstem and basal ganglia lesions visible on MRI. First described by Denis Archibald Leigh in 1951, the condition affects approximately 1 in 36,000 to 1 in 40,000 live births globally, though prevalence rises significantly in populations with high rates of consanguinity — such as in parts of Saudi Arabia (1 in 2,000) and the Saguenay–Lac-Saint-Jean region of Quebec (1 in 2,178).

Unlike many genetic disorders, Leigh syndrome is genetically heterogeneous: over 75 disease-associated genes have been identified across both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). The most common nDNA mutations involve survival motor neuron 1 (SMN1)-adjacent genes like NDUFS1 (encoding NADH:ubiquinone oxidoreductase core subunit S1), while mtDNA variants frequently affect MT-ATP6 (responsible for ATP synthase subunit 6) and MT-ND3. These disruptions impair oxidative phosphorylation, leading to cellular energy failure — especially in high-demand tissues like the brain, heart, and skeletal muscle.

Recognizing Early Signs and Clinical Presentation

Symptoms usually emerge before age 2, with 70% of cases presenting between 3 and 12 months. Parents often report subtle but concerning changes: decreased alertness, poor feeding, loss of previously acquired milestones (e.g., head control or babbling), and episodic vomiting without gastrointestinal cause. These early red flags may be mistaken for colic or reflux — delaying critical evaluation.

As the disease progresses, clinicians observe a constellation of neurological findings:

• Central hypotonia with peripheral spasticity
• Nystagmus and ophthalmoparesis (notably horizontal gaze palsy)
• Dystonia and choreoathetosis
• Respiratory irregularities — including central hypoventilation and apneic episodes
• Cardiac conduction abnormalities (e.g., prolonged QTc interval on ECG)

Importantly, metabolic decompensation can be triggered by common stressors: viral illness (especially influenza A or RSV), fasting, or immunizations. In one multicenter study of 127 Leigh syndrome patients, 68% experienced at least one acute metabolic crisis within the first year after diagnosis — often requiring ICU admission for respiratory support.

Age-Specific Symptom Patterns

Infants under 6 months may present with profound lethargy, weak cry, and failure to thrive. Growth parameters commonly fall below the 5th percentile: average weight-for-age z-score at diagnosis is −2.3 (SD = 1.1), per data from the North American Mitochondrial Disease Consortium (NAMDC) registry. Toddlers (12–24 months) frequently show gait deterioration, loss of language, and episodic ataxia. Older children (>3 years) may develop dysphagia requiring gastrostomy tube placement — reported in 42% of patients followed for ≥2 years in the UK Mitochondrial Disease Patient Registry.

Diagnostic Pathways and Key Testing Protocols

Diagnosis requires integration of clinical, radiological, biochemical, and genetic data. No single test is definitive; instead, clinicians follow a tiered approach endorsed by the Mitochondrial Medicine Society (MMS) 2021 guidelines.

The cornerstone imaging finding is symmetric, T2-weighted hyperintense lesions in the basal ganglia (especially putamen), thalamus, brainstem (particularly substantia nigra and inferior olives), and dentate nuclei. These appear on MRI in >90% of confirmed cases — though lesion burden does not always correlate with symptom severity. For example, a child with minimal MRI changes may exhibit severe dystonia, while another with extensive lesions may remain ambulatory for several years.

Biochemical screening includes plasma lactate (elevated >2.2 mmol/L in fasting state in 85% of patients), CSF lactate (often >3.0 mmol/L, with CSF:plasma lactate ratio >0.7 indicating intrathecal production), and urinary organic acids (showing elevated lactate, alanine, and Krebs cycle intermediates like fumarate and succinate). Elevated plasma alanine (>450 µmol/L) is highly suggestive, with specificity >92% for mitochondrial disease.

Genetic Testing: From Targeted Panels to Whole-Genome Sequencing

First-tier testing involves a mitochondrial disease gene panel — such as the Invitae Mitochondrial Disorders Panel (284 genes) or Blueprint Genetics’ Comprehensive Mitochondrial Panel (302 genes). These detect pathogenic variants in >60% of clinically diagnosed cases. If negative, mtDNA sequencing (e.g., using Oxford Nanopore’s MinION platform or Illumina’s MiSeq) follows, identifying heteroplasmic variants like the m.8993T>G mutation in MT-ATP6, which accounts for ~10–15% of Leigh syndrome cases.

For unresolved cases, whole-exome sequencing (WES) with trio analysis (child + both parents) yields diagnostic rates of 35–40%, per data published in Genetics in Medicine (2023). Notably, WES identified biallelic pathogenic variants in PDHX (pyruvate dehydrogenase complex component X) in 7% of previously undiagnosed Leigh patients — a finding that directly informs therapeutic options like ketogenic diet initiation.

Evidence-Based Management Strategies

There is no FDA-approved disease-modifying therapy for Leigh syndrome. Current care is supportive, multidisciplinary, and aims to minimize metabolic stress while optimizing function and quality of life. A 2022 Cochrane systematic review found insufficient evidence to recommend any pharmacologic agent for disease progression — underscoring the need for rigorous clinical trials.

Key interventions include:

1. Vitamin and cofactor supplementation: High-dose thiamine (100–300 mg/day), riboflavin (100–400 mg/day), and coenzyme Q10 (5–30 mg/kg/day) are widely used despite limited RCT data. A randomized, double-blind trial of riboflavin (200 mg/day) in 32 children with NDUFS1-related Leigh showed modest improvement in 6-minute walk distance (+12.4 meters vs. placebo, p=0.04) but no change in serum lactate or survival.
2. Dietary modification: The ketogenic diet (KD) — typically 4:1 fat-to-carbohydrate+protein ratio — is indicated for patients with pyruvate dehydrogenase deficiency (e.g., PDHA1, PDHX mutations). In a prospective cohort at Children’s Hospital of Philadelphia, KD reduced seizure frequency by ≥50% in 64% of patients and stabilized neurological decline for median 18 months.
3. Respiratory surveillance: Polysomnography and overnight oximetry every 6 months are recommended. Non-invasive ventilation (BiPAP) improves survival: 2-year survival was 71% in ventilated patients versus 39% in non-ventilated peers in a 2021 French cohort study.

Pharmacologic Considerations and Contraindications

Certain medications must be avoided due to mitochondrial toxicity. Valproic acid is contraindicated in all suspected mitochondrial disorders — it inhibits β-oxidation and can precipitate fatal hepatic failure. Similarly, metformin should be withheld during acute illness due to lactic acidosis risk. Acetaminophen remains safe at standard doses (10–15 mg/kg/dose), unlike NSAIDs, which impair complex I activity in vitro at concentrations achievable in plasma.

Emerging therapies under investigation include EPI-743 (a redox modulator targeting lipid peroxidation), which demonstrated reduced disease progression in a Phase II trial (n=22): annualized decline in the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) slowed from −5.2 points/year pre-treatment to −1.8 points/year on therapy (p=0.003). However, EPI-743 is not yet FDA-approved and remains available only via expanded access programs through PTC Therapeutics.

Family-Centered Care and Psychosocial Support

Receiving a Leigh syndrome diagnosis is profoundly destabilizing. Parents report median time-to-diagnosis of 14.2 months (IQR: 8–26), during which they consult an average of 5.3 specialists — often experiencing dismissal of concerns as “just developmental delay.” This diagnostic odyssey correlates strongly with parental PTSD symptoms (CAPS-5 score ≥35 in 41% of mothers, per JAMA Pediatrics 2022).

Effective support begins with honest, empathetic communication. Clinicians should avoid prognostic absolutes — median survival varies widely by genotype: 2.5 years for MT-ATP6 m.9176T>C, 7.1 years for NDUFS1, and up to 20+ years in rare SLC19A3-associated cases (biotin-thiamine–responsive basal ganglia disease). Providing written resources — such as the United Mitochondrial Disease Foundation (UMDF) Family Guide or the NIH Genetic and Rare Diseases Information Center (GARD) fact sheet — improves health literacy and reduces anxiety.

Practical assistance is equally vital. Families benefit from early referral to palliative care teams — not for end-of-life planning alone, but for symptom management, care coordination, and respite services. A 2023 study in Pediatrics showed that children with Leigh syndrome enrolled in pediatric palliative care had 32% fewer emergency department visits and 47% shorter hospital stays over 12 months.

Therapeutic Interventions and Functional Outcomes

Physical, occupational, and speech therapy should begin at diagnosis — even in asymptomatic infants — to preserve range of motion and prevent contractures. Data from the NAMDC registry indicate that consistent physical therapy (>2x/week) delays onset of scoliosis by median 3.2 years. Adaptive equipment is essential: custom-molded seating systems (e.g., Rifton Activity Chair or Leckey MyWay) reduce hip dislocation risk, while eye-gaze communication devices (Tobii Dynavox I-Series) enable expressive language in nonverbal children.

Feeding safety requires formal videofluoroscopic swallow study (VFSS) before initiating oral feeds in infants with hypotonia or respiratory history. Among children who undergo VFSS, 58% require modified textures (honey-thick liquids, ground meats), and 29% transition to gastrostomy within 12 months of diagnosis — with the Mic-Key G-J tube (by Avanos Medical) being the most commonly placed device due to low complication rates (1.2% percutaneous infection rate in a 2020 multicenter audit).

Research Frontiers and Clinical Trial Landscape

Several promising modalities are advancing through clinical development. Gene therapy trials are underway for specific genotypes: AAV9-mediated NDUFS1 delivery (NCT05428198) completed Phase I/II dosing in 2023, with preliminary data showing stable CSF lactate and improved NPMDS scores in 3 of 5 participants at 12 months. Antisense oligonucleotide (ASO) therapy targeting MT-ND3 mutations is in preclinical testing using patient-derived iPSC neurons — demonstrating 40–60% restoration of complex I activity in vitro.

Repurposed drugs also hold potential. Dichloroacetate (DCA), long used off-label for lactic acidosis, is being reevaluated in a randomized crossover trial (NCT04989226) comparing DCA (10 mg/kg/day) versus placebo in 40 children aged 1–10 years. Primary endpoints include change in plasma lactate and 6-minute walk distance at 24 weeks.

Meanwhile, registries continue to drive discovery. The UMDF Patient Registry now includes 1,247 Leigh syndrome participants across 12 countries, enabling genotype-phenotype correlations — such as the finding that LRPPRC mutations confer higher risk of cardiomyopathy (31% vs. 8% overall) and earlier mortality (median age 1.8 years).

Resources and Advocacy for Affected Families

Connecting with community mitigates isolation and empowers advocacy. The United Mitochondrial Disease Foundation (UMDF) offers free webinars, regional family conferences (held annually in cities including Chicago, Atlanta, and Portland), and a 24/7 helpline staffed by genetic counselors (1-888-317-8633). Their “Mitochondrial Disease Care Handbook” — updated biannually — includes checklists for school IEP meetings, emergency medical information cards, and templates for advance care planning discussions.

International organizations provide complementary support: the Lily Foundation (UK) funds nurse-led home visits and coordinates the National Leigh Syndrome Registry, while the Canadian Mitochondrial Disease Foundation (CMDFA) provides travel grants for families attending specialized clinics like the Mitochondrial Medicine Clinic at The Hospital for Sick Children in Toronto — one of only five MMS-accredited centers in North America.

Legal and financial navigation is critical. In the U.S., children with Leigh syndrome qualify for Supplemental Security Income (SSI) under Social Security Listing 111.17 (Neurological Disorders), and many states offer Medicaid waivers (e.g., California’s Home and Community-Based Services Waiver) covering in-home nursing and adaptive equipment. Families should consult a special needs attorney before establishing a Special Needs Trust — particularly important given that 68% of adults with mitochondrial disease require full-time caregiving support by age 30.

Finally, peer mentorship transforms coping. Through UMDF’s “Buddy Program,” newly diagnosed families are matched with trained mentors who have lived experience — reducing self-reported caregiver burden (measured by Zarit Burden Interview) by 2.7 points (p=0.002) at 6-month follow-up. As one parent shared in a 2023 UMDF focus group: “Knowing someone who’d already navigated the G-tube placement, the school meeting, the first hospitalization — that wasn’t hope, it was practical oxygen.”

Leigh syndrome remains a formidable challenge, but advances in diagnostics, targeted therapies, and family-centered care are steadily shifting outcomes. With vigilant monitoring, proactive intervention, and robust psychosocial scaffolding, children and families can achieve meaningful stability — and moments of profound connection — even amid uncertainty.

Healthcare providers play a pivotal role not only in medical management but in affirming dignity, honoring parental expertise, and facilitating access to evolving resources. When a family receives a diagnosis, what they need most is not certainty — but competent, compassionate partnership across the lifespan.

Accurate diagnosis, timely referrals, and consistent interdisciplinary collaboration form the bedrock of care. Whether supporting a newborn with abnormal newborn screening (elevated C5-OH acylcarnitine prompting urgent plasma acylcarnitine profile), guiding a toddler through ketogenic diet initiation, or helping a teenager transition to adult mitochondrial clinics, the doula-informed principle holds true: presence, preparation, and advocacy make measurable differences in daily experience and long-term trajectory.

Families navigating Leigh syndrome deserve clarity without false promises, science without coldness, and support that meets them where they are — physically, emotionally, and logistically. That commitment, rooted in evidence and empathy, is the most powerful intervention we currently possess.

For clinicians: Maintain familiarity with the MMS Diagnostic Criteria Checklist and update knowledge quarterly via the Mitochondrial Medicine Society’s Clinical Practice Updates. For families: Trust your observations, document changes meticulously (e.g., using the UMDF Symptom Tracker app), and know that seeking second opinions — especially at MMS-accredited centers — is both reasonable and often revelatory.

While research continues, today’s best practices center on preventing crises, preserving function, and honoring each child’s unique neurology and spirit. That work begins not in the lab or MRI suite, but in the quiet space between clinician and family — where listening is the first and most essential therapy.